drugset / Trial / NCT00085163
Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon
Phase 3
Completed
European Organisation for Research and Treatment of Cancer - EORTC
Arbeitsgemeinschaft fur Internistische Onkologie · collabDutch Colorectal Cancer Group (DCCG) · collabEORTC GI Group (EORTC 40023) · collabEgyptian Foundation For Cancer Research · collabFederation Francophone de Cancerologie Digestive · collabGCCD-APIO - Grupo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação · collabGOCCI - Gruppo Oncologico Chirurgico Cooperativo Italiano · collabGOIRC - Gruppo Oncologico Italiano di Ricerca Clinica · collabGruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente · collabOncológica · collabOnkologie · collabSG - Scandinavian Group · collabTTD - Grupo Español para el Tratamiento de Tumores Digestivos · collab
RandomizedDouble-blindTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether fluorouracil and leucovorin are more effective with or without celecoxib in treating resected stage III adenocarcinoma (cancer) of the colon. PURPOSE: This randomized phase III trial is studying celecoxib, fluorouracil, and leucovorin to see how well they work compared to fluorouracil and leucovorin in treating patients who have undergone surgery for stage III colon cancer.
Timeline
- Start
- 2004-03
- Primary completion
- 2005-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | — | Oral |
| Background | Leucovorin | Small molecule | — | Intravenous |
| Background | fluorouracil | Small molecule | — | Intravenous |